Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension PeriodCompleted
NCT03414736Phase 1Updated Apr 25, 2022
Sponsor: Sanofi
Type 2 Diabetes Mellitus
United States
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating InsulinCompleted
NCT02967224Phase 4Updated Apr 25, 2022
Sponsor: Sanofi
Diabetes Mellitus, Type 2
Brazil, France, Germany, Ireland, Romania +2 more
Postmarketing Surveillance Study for Use of Menactra® in the Republic of KoreaCompleted
NCT02864927Phase 4Updated Apr 25, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningitis · Meningococcal Meningitis · Meningococcal Infections
South Korea
Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of SotagliflozinCompleted
NCT03063580Phase 1Updated Apr 25, 2022
Sponsor: Sanofi
Diabetes Mellitus
France
Sotagliflozin Multiple-dose Study in Healthy Chinese SubjectsCompleted
NCT03909451Phase 1Updated Apr 25, 2022
Sponsor: Sanofi
Diabetes Mellitus
China
Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin TreatmentCompleted
NCT02967237Phase 4Updated Apr 25, 2022
Sponsor: Sanofi
Diabetes Mellitus, Type 2
France
A National Study in Patients With Unexplained SplenomegalyCompleted
NCT04430881N/AUpdated Apr 25, 2022
Sponsor: Sanofi
Gaucher Disease · Splenomegaly
France
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese SubjectsCompleted
NCT03376802Phase 1Updated Apr 25, 2022
Sponsor: Sanofi
Type 2 Diabetes Mellitus
United States
Scintigraphy Study to Compare the Antireflux Activity of the Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult SubjectsCompleted
NCT03065816Phase 1Updated Apr 25, 2022
Sponsor: Sanofi
Gastroesophageal Reflux Disease
United Kingdom
Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in IndiaCompleted
NCT02451358Phase 3Updated Apr 19, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza
India
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination RegimenCompleted
NCT01587040Phase 1, Phase 2Updated Apr 19, 2022
Sponsor: Sanofi
Neoplasm Malignant
United States, Belgium, France, Spain
Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian FederationCompleted
NCT01890759Phase 3Updated Apr 19, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningitis · Meningococcal Infection
India, Russia
Immunogenicity and Safety of a Purified Vero Rabies VaccineCompleted
NCT03145766Phase 2Updated Apr 19, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Rabies Virus
United States
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)Completed
NCT03205163Phase 1, Phase 2Updated Apr 19, 2022
Sponsor: Bioverativ, a Sanofi company
Hemophilia A
United States, Japan
Prospective Analysis of Hypersensitivity Reactions to OxaliplatinCompleted
NCT00831571N/AUpdated Apr 18, 2022
Sponsor: Dana-Farber Cancer Institute
Colorectal Cancer · Esophageal Cancer · Gastric Cancer · Small Bowel Cancer
United States
Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular DegenerationTerminated
NCT01367444Phase 1, Phase 2Updated Apr 14, 2022
Sponsor: Sanofi
Stargardt's Disease
United States, France
Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver DiseaseWithdrawn
NCT03437720Phase 2Updated Apr 13, 2022
Sponsor: Sanofi
Non-alcoholic Steatohepatitis · Type 2 Diabetes Mellitus
Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy SubjectsCompleted
NCT03310944Phase 1Updated Apr 13, 2022
Sponsor: Sanofi
Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus
Germany
Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and HypertensionCompleted
NCT02842359Phase 4Updated Apr 13, 2022
Sponsor: Sanofi
Type 2 Diabetes Mellitus
South Korea
Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the KneeCompleted
NCT02845271Phase 2Updated Apr 13, 2022
Sponsor: Genzyme, a Sanofi Company
Osteoarthritis
Germany
Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa TreatmentCompleted
NCT03687333Phase 4Updated Apr 13, 2022
Sponsor: Genzyme, a Sanofi Company
Glycogen Storage Disease Type II
China
An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia ACompleted
NCT02234323Phase 3Updated Apr 11, 2022
Sponsor: Bioverativ, a Sanofi company
Hemophilia A
United States, Australia, Brazil, Canada, France +9 more
Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)Terminated
NCT03260868Phase 4Updated Apr 7, 2022
Sponsor: Sanofi
Type 1 Diabetes Mellitus
United States, Canada
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the USCompleted
NCT03282240Phase 3Updated Apr 7, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza
United States
Immune Tolerance Induction StudyTerminated
NCT00701701Phase 4Updated Apr 7, 2022
Sponsor: Genzyme, a Sanofi Company
Pompe Disease · Glycogen Storage Disease Type II (GSD-II) · Glycogenesis 2 Acid Maltase Deficiency
United States, Israel

Previous page Next page